The shareholders of CS MEDICA A/S (“CS MEDICA” or the “Company”) are hereby notified of an Extraordinary General Meeting to be held on Friday, June 28^th 2024 at 10:00 AM via TEAMS.

CS MEDICA is convening this Extraordinary General Meeting (EGM) to discuss and approve key strategic initiatives, including the listing of shares on the German Stock Exchange and the IPO of its wholly-owned subsidiary, CANNORDIC A/S.

Proposed Agenda:

1. Authorization for Listing – Authorization for the company’s board of directors to list CS MEDICA shares on the German Stock Exchange.
2. Subsidiary IPO – Proposal to list the company’s subsidiary, CANNORDIC A/S, on the German Stock Exchange via an initial public offering (IPO) at a valuation of DKK 223.5 million (€30 million). Concurrent proposal to increase the number of shares of CANNORDIC A/S from the current 500 units of DKK 1,000 to 5,000,000 units of DKK 0.1, maintaining the same voting rights.

For more detailed information regarding the spin-off and listing of CANNORDIC A/S, please refer to the separate press release issued on June 10th, 2024.
Registration for the EGM: The registration date is June 21st, 2024. Only shareholders on this date can participate and vote at the extraordinary general meeting.

To obtain access to the general meeting and thus be able to participate and vote, a shareholder must request an admission card no later than 2 days before the general meeting, according to section 5.9 of the articles of association. Such a request must be made to Gitte Lund Henriksen via email at glh@cs-medica.com. The request must be received no later than June 21st, 2024, at 11:59 PM (CET). A shareholder can also request an admission card for a proxy holder who attends the general meeting on behalf of the shareholder. The request must follow the same guidelines. The shareholder must fill in and sign the proxy and postal voting form, enclosed as Schedule 1, which can also be found on the Company’s website www.cs-medica.com. The proxy must bring the admission card and the original form to the general meeting.

The total number of votes as of the date of this notice is 12,322,635. The board has already received 8,842,160 positive votes, corresponding to 72%.
Participation: To be entitled to participate in the general meeting, shareholders whose shares are registered in the name of a nominee must temporarily re-register their shares in their own names in the share register. Such registration must be duly effected in the share register on June 23rd, 2024, and the shareholders must, therefore, advise their nominees well in advance of such a date.

The shareholders have the right to ask questions about the issues on the agenda to be discussed at the general meeting. The questions can be made in writing before or at the general meeting. If possible, the answer will be made at the general meeting or made available to the shareholders no later than two weeks after the general meeting.

All material mentioned in this notice can be obtained from Gitte Lund Henriksen via email at glh@cs-medica.com. The material will only be forwarded by email, and thus the email address must be specified.

EGM Details: Shareholders will be entitled to vote by submitting postal vote forms before the meeting. Information about the resolutions passed at the meeting will be made public after the extraordinary general meeting.

Date and Time: June 28th, 2024, from 10:00-10:30 AM CET

Venue: Via TEAMS

Registration for. EGM: glh@cs-medica.com

Power of Attorney: Schedule 1  >>

CS MEDICA A/S: On behalf of the board of directors

Flemming Heegaard, Chairman

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.
CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes.